By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cubist Pharmaceuticals, Inc. 

65 Hayden Avenue

Lexington  Massachusetts  02421  U.S.A.
Phone: 781-860-8660 Fax: 781-861-0566

There’s something special about working at Cubist Pharmaceuticals.

We provide a progressive, flexible work environment and a highly competitive total rewards program designed to meet your work/life needs now and in the future. In our product, our pipeline and in our supportive culture, Cubist demonstrates its continuing commitment of excellence to our employees and our shareholders.

Cubist is a bio-pharmaceutical company focused on the research, commercial¬ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment. CUBICIN® , (daptomycin for injection), our marketed product, has been used in the treatment of more than an estimated 1.1 million patients with serious and sometimes life-threatening infections. CUBICIN has generated hundreds of millions of dollars in annual sales that helped propel Cubist into one of the Commonwealth's best-performing firms as evidenced by recent recognition. Cubist was ranked among Top Pharmas on the Scrip 100 List, while Forbes recently listed Cubist as one of 14 "Productivity Powerhouses." Cubist appeared in The Boston Globe's 2010 annual list of the "Top Places to Work" in Massachusetts (for the third consecutive year).

Mass High Tech announced that Cubist ranked 13th among the top 30 Fastest-Growing Public Technology Companies in New England for 2010 and was one of only ten pharmaceutical companies to make that list. Cubist also debuted as the 31st overall company and top pharmaceutical company named to FORTUNE's 2010 List of 100 Fastest-Growing Companies, and was named to the 2010 Deloitte Technology Fast 500™ for the sixth consecutive year.

Key Statistics

Ownership: Public

Web Site: Cubist Pharmaceuticals, Inc.
Employees: ~600
Symbol: CBST

Company News
Cubist Pharmaceuticals, Inc. (CBST) To Present At August Investor Conference 7/28/2014 8:46:31 AM
Cubist Pharmaceuticals, Inc. (CBST) Strikes Agreement With Competitor To Delay Generic Cubicin 7/24/2014 7:04:19 AM
Cubist Pharmaceuticals, Inc. (CBST) Reports Second Quarter 2014 Financial Results 7/23/2014 4:55:15 PM
Cubist Pharmaceuticals, Inc. (CBST) To Announce Second Quarter 2014 Financial Results On Tuesday, July 22, 2014 7/15/2014 10:13:27 AM
Cubist Pharmaceuticals, Inc. (CBST) Wins FDA Approval For MRSA Antibiotic Sivextro 6/20/2014 4:40:22 PM
Cubist Pharmaceuticals, Inc. (CBST) Announces Acceptance Of Ceftolozane/Tazobactam New Drug Application With Priority Review 6/20/2014 10:40:44 AM
Cubist Pharmaceuticals, Inc. (CBST) Selects TransPerfect Trial Interactive’s Trial Interactive Platform As Its eTMF Solution 6/16/2014 10:29:16 AM
Cubist Pharmaceuticals, Inc. (CBST) Announces Publication Of Pivotal Data From SIVEXTRO™ (tedizolid phosphate) ESTABLISH-2 Clinical Trial In The Lancet Infectious Diseases 6/6/2014 8:40:58 AM
Cubist Pharmaceuticals, Inc. (CBST)To Present At June Investor Conferences 6/2/2014 6:41:38 AM
Cubist Pharmaceuticals, Inc. (CBST) Presents Detailed Results From Positive Phase 3 Trials Of Ceftolozane/Tazobactam At 2014 European Congress Of Clinical Microbiology and Infectious Diseases (ECCMID) 5/12/2014 9:17:35 AM